FDA hits Neumora with clinical hold for schizophrenia drug after preclinical data showed convulsions in rabbits
15 Apr 2024
Phase 1
Neumora Therapeutics has hit a road block to becoming a major neuroscience player, with the FDA placing a clinical hold on a Phase 1 study for one of its early-stage assets in schizophrenia.
The company said that the trial is on hold following “recently available” preclinical data for its drug dubbed NMRA-266 which showed convulsions in rabbits. Neumora said that 30 patients in the Phase 1 have already taken the drug, a modulator of the M4 muscarinic receptor, and no convulsions have been reported.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.